Charles River Offers More In Vitro Oncology Services via InSphero’s 3D Solutions

Media Coverage
breast cancer

FierceBiotech

Under a new deal, Charles River will license its patient-derived xenograph (PDX) tumors to InSphero, and in return, InSphero will provide its 3D cell culture capabilities and help Charles River build in vitro 3D tumor microtissues derived from these PDXs. InSphero uses a scaffold-free 3D microtissue technology, which allows cells to self-assemble into 3D assay-ready microtissues.

Read the full article